Voyager and ReGenX Partner to Treat Neurodegenerative Diseases

Cambridge, MA-based Voyager Therapeutics has entered into a licensing deal with ReGenX Biosciences, a Washington, DC-based gene therapy company, to use ReGenX’s NAV® vectors. Voyager plans to use these vectors to develop new gene therapies for neurodegenerative disease, such as ALS, Huntington’s and Friedreich’s Ataxia (for more background, see Feb 2014 News). ReGenX’s technology uses recombinant adeno-asociated viral (AAV) vectors optimized for efficient delivery of genetic material into cells of interest. Voyager obtained a non-exclusive license for an undisclosed up-front fee and milestone payments.

Cambridge, MA-based Voyager Therapeutics has entered into a licensing deal with ReGenX Biosciences, a Washington, DC-based gene therapy company, to use ReGenX’s NAV® vectors. Voyager plans to use these vectors to develop new gene therapies for neurodegenerative disease, such as ALS, Huntington’s and Friedreich’s Ataxia (for more background, see Feb 2014 News). ReGenX’s technology uses recombinant adeno-asociated viral (AAV) vectors optimized for efficient delivery of genetic material into cells of interest. Voyager obtained a non-exclusive license for an undisclosed up-front fee and milestone payments.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail